Фулвестрант (Фазлодекс): настоящее и будущее в терапии рака молочной железы

1. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 2002; 76: 27–36.
2. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001; 28: 291–304.
3. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867–73.
4. Katzenellenbogen JA, O’Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996; 10: 119–31.
5. Fawell SE, White R, Hoare S et al. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990; 87: 6883–7.
6. Parker MG. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 1993; 26: 131–7.
7. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106 (Pt 4): 1377–88.
8. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992; 89: 4037–41.
9. Bergman L, Beelen ML, Gallee MP et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356: 881–7.
10. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527–37.
11. Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001; 7(Suppl): 4369–75.
12. Sismondi P, Biglia N, Volpi E et al. Tamoxifen and endometrial cancer. Ann N Y Acad Sci 1994; 734: 310–21.
13. Dukes M, Miller D, Wakeling AE, Waterton JC. Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 1992; 135: 239–47.
14. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002; 87: 1354–9.
15. McClelland RA, Manning DL, Gee JM, et al. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Res Treat 1996; 41: 31–41.
16. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor and estrogen receptor in human breast cancer. J Biol Chem 1978; 253: 2223–38.
17. Hutcheson IR, Knowlden JM, Madden T-A et al. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003; 81: 81–93.
18. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl.estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61: 6739–46.
19. Gutteridge E, Robertson JFR, Cheung KL et al. Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer – final results. Breast Cancer Res Treat 2004; 86: 4086, abs.
20. Johnston SR. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001; 7: 4376–87.
21. Hu XF, Veroni M, De Luise M, et al. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993; 55: 873–6.
22. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 1995; 61: 529–34.
23. Osborne CK, Jarman M, McCague R et al. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 1994; 34: 89–95.
24. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746–50.
25. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386–95.
26. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396–403.
27. Robertson JF, Osborne CK, Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women – a prospective combined analysis of two multicenter trials. Cancer 2003; 98: 229–38.
28. Howell A, Pippen J, Elledge RM et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005; 104: 236–9.
29. Mauriac L, Pippen JE, Quaresma Albano J et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003; 39: 1228–33.
30. Vergote I, Robertson JFR, Kleeberg U et al. Postmenopausal women who progress on fulvestrant (‘Faslodex’) remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003; 79: 207–31.
31. Steger G, Bartsch R, Wenzel C et al. Fulvestrant (Faslodex®) in metastatic breast cancer. Breast Cancer Res Treat 2003; 82 (Suppl 1): 104 Abstract 437.
32. Franco S, Perez A, Tan-Chiu E et al. Response to fulvestrant in heavily pretreated postmenopausal women: a singlecenter experience. Breast Cancer Res Treat 2004; 88: 103–8.
33. Petruzelka L, Zimovjanova M, Konopasek B et al. Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy – updated results from an expanded access programme. Ann Oncol 2004; 15 (Suppl 3): 136P, iii36 abs.
34. Nicholson RI, Gee JMW, Knowlden J et al. The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 2003; 80 (Suppl 1): S29–34.
35. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758–67.
36. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101–9.
37. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391–8.
38. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802–10.
39. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
40. Buzdar A, Macahilig C. How rapidly do oncologists respond to clinical trial data. Oncologist 2005; 10: 15–21.
41. Shim WS, Conaway M, Masamura S et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000; 141: 396–405.
42. Chan CM, Martin LA, Johnston SR et al. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002; 81: 333–41.
43. Martin L-A, Farmer I, Johnston SRD et al. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003; 278: 30458–68.
44. Jeng MH, Shupnik MA, Bender TP et al. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology 1998; 139: 4164–74.
45. Perey L, Paridaens R, Nol_e F et al. Fulvestrant (FaslodexTM) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 2004; 88 (Suppl 1): 6048. S236 abs.
46. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: a phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat 2004; 88 (Suppl. 1): S38 Abstract 409.
47. Nicholson RI, Hutcheson IR, Harper ME et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001; 8: 175–82.
48. McClelland RA, Barrow D, Madden TA et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001; 142: 2776–88.
49. Sommer A, Hoffmann J, Lichtner RB et al. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 2003; 85: 33–47.
50. Kurebayashi J, Okubo S, Yamamoto Y, Sonoo H. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 2004; 11: 38–41.
51. Okubo S, Kurebayashi J, Otsuki T et al. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004; 90: 236–44.
52. Gee JMW, Harper ME, Hutcheson IR et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003; 144: 5105–17.
53. Kunisue H, Kurebayashi J, Otsuki T et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti- oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 2000; 82: 46–51.
54. Pietras RJ, Marquez DC, Chen HW et al. Improved antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 2003; 82 (Suppl. 1): 12, Abs. 22.
55. Robertson JFR, Semiglazov V, Gee JM, Armstrong J. Effects of fulvestrant in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer Suppl 2004; 2: 73, abs 59.
56. Piccart-Gebhart MJ, Loi SM. Fulvestrant – ready to start its journey in the breast cancer adjuvant endocrine world. Eur J Cancer 2005; 41: 341–3.

A. Howell

Источник: Critical Reviews in Oncology/Hematology 2006; 57: 265–273.